Agilon Health Q3 2026 Earnings: Lower Medical Costs Restore Profitability
Agilon Health reported Q3 2026 revenue of $1.52 billion and diluted EPS of $1.97, returning to GAAP profitability. The turnaround was driven by a lower medical services expense ratio of 88.5% and stronger contract economics, offsetting an 8% decline in total platform membership. Consequently, management raised its full-year 2026 guidance, projecting higher revenue and adjusted EBITDA. Key risks for investors include the sustainability of favorable prior-period claims development, continued membership contraction, and rising non-medical expenses.
agilon health (NYSE: AGL) reported Q3 2026 revenue of $1.52 billion, up 6% from $1.44 billion, and diluted EPS of $1.97 compared with a loss of $6.65 a year earlier. For the quarter ended September 30, the company returned to GAAP profitability as its medical services expense ratio fell to 88.5% from 104.0%, more than offsetting lower membership and higher other medical and administrative expenses.
Core Earnings Results
Revenue increased by approximately $84 million year over year, while total expenses declined by about $71 million. The combination moved agilon from a $131 million operating loss to $24 million of operating income.
The largest driver was lower medical services expense, which declined even as medical services revenue increased. Adjusted EBITDA also turned positive, although this non-GAAP measure includes contributions from unconsolidated ACO entities.
| Metric | Q3 2026 | Q3 2025 | Year-Over-Year Change |
|---|---|---|---|
| Revenue | $1.519 billion | $1.435 billion | +6% |
| Medical services expense ratio | 88.5% | 104.0% | -15.5 percentage points |
| Operating income (loss) | $24.1 million | $(131.3) million | Turned positive |
| Net income (loss) | $34.9 million | $(110.2) million | Turned positive |
| Diluted EPS | $1.97 | $(6.65) | Turned positive |
| Adjusted EBITDA | $63.7 million | $(91.5) million | Turned positive |
Membership and Revenue Drivers
Revenue growth contrasted with continued membership contraction. Management attributed the decline in members primarily to its profitability-focused contracting approach, previously announced market exits, and measured growth strategy.
Despite fewer members, revenue rose because of higher-than-expected burden-of-illness performance, payer contracting, and improved pricing. This indicates that revenue per covered member and contract economics outweighed the effect of lower volume during the quarter.
| Operating Metric | Q3 2026 | Q3 2025 | Year-Over-Year Change |
|---|---|---|---|
| Medicare Advantage members | 454,000 | 503,000 | -10% |
| ACO model beneficiaries | 112,000 | 115,000 | -3% |
| Total platform members | 566,000 | 618,000 | -8% |
| Average Medicare Advantage members | 488,000 | 510,000 | -4% |
The membership figures are end-of-period totals except for average Medicare Advantage members. ACO model entities are included in the platform membership count but are not consolidated into agilon’s reported financial results.
Lower Medical Costs Drove the Profit Turnaround
Medical services expense declined to $1.344 billion from $1.489 billion, even as medical services revenue increased to $1.518 billion. That divergence reduced the medical services expense ratio by 15.5 percentage points and was the central reason operating income, net income, and adjusted EBITDA all turned positive.
The Q3 ratio included favorable claims development related to the first half of 2026. Investors therefore need to distinguish underlying current-period medical-cost performance from benefits tied to updated estimates for earlier claims.
Other expense categories moved in the opposite direction. Other medical expenses rose to $78.0 million from $13.5 million, while general and administrative expense increased to $67.1 million from $56.2 million. Q3 stock-based compensation included in the adjusted EBITDA reconciliation also rose to $18.9 million from $7.5 million.
The unconsolidated ACO entities contributed $11 million to adjusted EBITDA, down from $18 million a year earlier. This contribution is relevant when comparing the non-GAAP result with agilon’s consolidated GAAP performance.
Nine-Month Cash Flow and Balance Sheet
Operating cash flow was $16.3 million for the first nine months of 2026, compared with an $85.2 million outflow in the same period of 2025. This is a year-to-date figure rather than a standalone Q3 cash flow result.
Cash conversion nevertheless trailed nine-month net income of $101.8 million. Changes in operating assets and liabilities used $134.4 million of cash, and net receivables increased to $1.017 billion at September 30 from $673.8 million at the end of 2025.
At quarter-end, agilon reported $312 million of cash, cash equivalents, and marketable securities, along with $32 million of total debt. Its unconsolidated ACO entities separately held $74 million of cash.
FY2026 Guidance
Following the Q3 results, agilon raised its FY2026 revenue, membership, and adjusted EBITDA outlook while lowering its expected medical services expense ratio. The largest revision was in adjusted EBITDA, with both ends of the range moving materially higher.
| Metric | Updated FY2026 Guidance | Previous Guidance | Change |
|---|---|---|---|
| Revenue | $5.870–$5.890 billion | $5.775–$5.860 billion | Raised |
| Medical services expense ratio | 90.3%–90.5% | 91.4%–91.9% | Lowered |
| Adjusted EBITDA | $145–$155 million | $75–$95 million | Raised |
| Ending Medicare Advantage members | 445,000–450,000 | 435,000–445,000 | Raised |
| Ending ACO model beneficiaries | 108,000–112,000 | 100,000–105,000 | Raised |
| Total ending platform members | 553,000–562,000 | 535,000–550,000 | Raised |
| Average Medicare Advantage members | 451,000–453,000 | 438,000–443,000 | Raised |
| Geography entry costs | $15 million | $15 million | Unchanged |
The company expects unconsolidated ACO entities to contribute approximately $40 million to $45 million to full-year adjusted EBITDA. It did not provide GAAP net income guidance or reconcile projected adjusted EBITDA to net income because certain items, including stock-based compensation, could not be forecast without unreasonable effort.
Risks Investors Need to Watch
- Claims development could affect the apparent medical-cost trend. Q3’s 88.5% medical services expense ratio included favorable development associated with claims from the first half of 2026.
- Membership remains below the prior-year level. Total platform membership declined 8%, including a 10% reduction in Medicare Advantage members, reflecting market exits and selective contracting.
- Revenue growth depends on contract economics and risk capture. Improved pricing, payer contracting, and burden-of-illness performance offset lower membership this quarter, making their durability important for future revenue.
- Non-medical expense pressure continued. Other medical expenses, general and administrative costs, and stock-based compensation all increased year over year despite the improvement in core medical services expense.
- Adjusted EBITDA includes unconsolidated operations. ACO entities contributed to adjusted EBITDA even though their results are not consolidated, creating an important scope difference between GAAP and non-GAAP performance.
Summary
Agilon’s Q3 2026 turnaround was driven primarily by lower medical services expense and improved contract economics rather than membership growth. Revenue increased despite fewer members, while the lower medical services expense ratio moved the company back to operating and net profitability. The raised full-year outlook points to improved 2026 economics, but the durability of claims performance, continued membership contraction, and rising non-medical expenses remain the main areas to monitor.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.